From Hype to Obscurity: How a Once-$100M Medical Patent Collapsed to a $30K Fire Sale

In the narrative of medical innovation translation, we seem to always hear those exciting success stories, but in fact, failure is the main theme of this storyline. According to the latest statistical data, the conversion rate of medical scientific and technological achievements in China is less than 10%, indicating that most medical innovation projects have failed to cross the "Valley of Death."

The reasons for this are, of course, varied, but the most critical factor lies in scientists’ insufficient understanding of the market. More focused on technology and lacking an accurate grasp of the industry, they often tend to go down a rabbit hole during the commercialization process, gradually leading innovative projects that should have shone in the marketplace astray until they disappear from public view.

Such “regrets” are far from rare. Professor Wang Liqiu (a pseudonym) is one of the central figures in this narrative. His innovative project suffered a double “Waterloo” within just one year: first, market interest waned, dropping from fifteen investor meetings per day at the outset to complete indifference by the end; second, the project’s valuation plummeted, from a peak of RMB 100 million during the height of market enthusiasm to a mere RMB 300,000 in transaction value amid subsequent market apathy. This stark contrast can aptly be described as “worlds apart.”

So, how exactly are the “regrets” and “discrepancies” in between created?

On a summer day in 2020, despite it being a weekend, Professor Wang Liqiu was extremely busy, as he had to meet with 15 investment firms within the day. Some meetings were held online, while others took place in person; yet regardless of the format, these “visitors” shared a single, straightforward objective: to secure an early position as investors in Professor Wang Liqiu’s innovative project.

In fact, the considerable buzz in the investment market was no accident; it stemmed primarily from the strong competitive edge of Professor Wang Liqiu’s innovative project at the time. This advantage lay not only in the groundbreaking originality of the technology itself but also in its vast potential for market application—two factors that firmly captured the interest of investment firms.

However, these investment firms did not achieve their desired outcomes following the meetings, as Professor Wang Liqiu was too “assertive,” particularly regarding the specific transaction amount. Professor Wang remained uncompromising, insisting on a single price; even when some investment firms offered up to RMB 100 million, he remained unmoved.

According to Professor Wang Liqiu’s recollections, he met with nearly 150 investment institutions that year, including many of China’s top-tier firms. However, despite their prestigious reputations and highly attractive terms, none were able to win him over at the time, as they could never reach an agreement on valuation.

Professor Wang Liqiu’s unwavering stance on pricing stems primarily from his strong “self-protection instinct” triggered by external environmental pressures.

For Professor Wang Liqiu at that time, due to a lack of accurate understanding of the industry and market environment, he was uncertain about the true value of his innovative project and unaware of what equity stake he should hold in the future. During interactions with investment firms, he habitually assumed the role of a “victim,” often suspecting that he had fallen into their traps. He was also plagued by recurring concerns such as, “If I proceed with the transaction at this price, will I be at a disadvantage?”

Therefore, after conducting a “self-assessment,” Professor Wang Liqiu proposed a price that he considered relatively safe. However, this “seemingly reasonable” price had clearly not been validated by the market and far exceeded the expectations of investment institutions, ultimately leading to an acrimonious breakdown in negotiations.

However, the investment community is a closed and fast-moving ecosystem; no one will wait for you indefinitely. After Professor Wang Liqiu rejected a number of investment firms on the same grounds, subsequent investors began to withdraw their interest. As a result, Professor Wang eventually found himself meeting with only a handful of investment firms per week or even per month, a stark contrast to the earlier “flood” of interest.

Subsequently, there were no further investments, as alternative technologies had emerged on the market with pricing more aligned with market demand. As a result, Professor Wang Liqiu’s innovative project quickly lost its initial “halo” and gradually faded from market attention.

Professor Wang Liqiu, who had experienced dramatic highs and lows in a short period, was deeply perplexed. He found it hard to believe that the “treasure” he had held so tightly had lost its due value in the market within such a brief timeframe. Disheartened and losing patience, he enlisted a friend’s help to connect with a medical device company, ultimately transferring the technology for RMB 300,000.

If calculated precisely, only 243 days elapsed between the initial offer of a RMB 100 million transaction by an investment institution and the final deal closed at RMB 500,000. In reality, however, Professor Wang Liqiu had less than three months for genuine deliberation, as technological iterations in the healthcare sector are extremely rapid; missing the optimal window is akin to missing the entire spring.

Many people are wondering: When did Professor Wang Liqiu roughly begin to realize his decision-making error? Was it when the number of investment institutions significantly decreased, or at the time when the technology was ultimately transferred to enterprises?

In fact, neither was the case. Professor Wang Liqiu truly gained clarity only in the second year after the technology transfer, when a colleague recounted a similar experience. Viewing the situation from an outsider’s perspective, Professor Wang immediately recognized his own “passivity” and “stubbornness” throughout the entire commercialization process.

The term “passive” is used because a lack of accurate market interpretation prevented Professor Wang Liqiu from objectively evaluating his own innovative projects, leaving him with no choice but to be led by investment institutions, uncertain as to whether the direction taken was right or wrong.

Why is it also described as “stubborn”? In fact, these elements are closely interlinked. Because he was in a “passive” position, he sought to protect himself by maintaining a relatively safe vantage point. For Professor Wang Liqiu at that time, this “safe vantage point” was the firmly held, non-negotiable transaction price he had determined.

Professor Wang Liqiu was clearly missed. In reality, such regrettable oversights are not uncommon in the medical field, both historically and at present. How, then, should the growing number of scientists positioned along the innovation chain act to prevent similar regrets from recurring?

From the perspective of VCBeat, the most critical factor is for scientists to appropriately set aside their “pride” and courageously embrace the market. This concept of “embracing the market” encompasses three layers of meaning:

First, identify the intersection between clinical practice and the market, and choose a path with a clearly visible endpoint. In any era, the essence of medical innovation is to address unresolved clinical issues. Therefore, when pursuing innovation, the primary step is to closely align with clinical needs. Subsequently, one should leverage these clinical needs to identify market demands. Only by doing so can we accurately anticipate future trends in the healthcare sector, minimize detours during the translation process, and ultimately achieve greater returns.

Second, identify the maximum value between technology and the market, and select an optimal path leading to the end goal. For the vast majority of scientists, there is a common misconception during innovation and commercialization: they habitually believe that their innovative projects must lead to entrepreneurship, or even culminate in an initial public offering (IPO).

This is certainly the optimal outcome, but it must be pursued within one’s means. Not every innovative project possesses the characteristics necessary to become a viable enterprise, and commercialization is not limited to startup formation; technology licensing is also a feasible pathway. The specific choice should be determined by maximizing the ratio of the innovation project’s intrinsic attributes (numerator) to market conditions (denominator). Following this approach will significantly increase the success rate of commercialization.

Third, identify complementary points between individual capabilities and market demands to select the optimal partners for commercialization. With a clear destination and pathway established, the remaining challenge is execution. However, relying solely on individual effort is insufficient, as personal capacity has inherent ceilings, and one’s perspective and strategic vision are limited. This is particularly true for scientists who have long operated within closed academic ecosystems, where their market-oriented competencies tend to be relatively weak. Therefore, it is essential to identify ideal partners who can provide genuine support throughout this forward-moving journey.

Take the selection of investment institutions as an example. First and foremost, one should not focus solely on capital; instead, a comprehensive evaluation is essential. Factors such as the institution’s professional expertise, its capacity for long-term partnership, and its ability to provide high-quality resources must be considered. These elements are particularly critical for startups in their early stages.

Secondly, in terms of pacing, it is essential to keenly observe market changes and respond appropriately. One should not subjectively overestimate the intrinsic value of innovative projects; instead, one should evaluate them rationally from a market perspective, initiate fundraising at the right juncture, and ensure its completion within the designated timeframe.

The ultimate goal is precision—avoiding the “hammer looking for a nail” approach. Throughout the development of a startup, the value-add required at each stage varies significantly, necessitating precise alignment with suitable investment institutions at different phases. For instance, in the early stages, startups tend to select relatively familiar investors based on mutual trust. In the mid-to-late stages, they can shift their focus toward corporate venture capital (CVC) firms, as these investors possess the deepest understanding of the project and its market, and can bring additional industry resources to the startup.

Wang Jie, a professor at the Jiangsu Provincial Institute of Clinical Medicine and founder of Sinomai Medical, once stated, “For scientists engaged in the process of translation, it is crucial to properly manage the ‘starting point’ and ‘critical nodes,’ as they are intrinsically interconnected. If you fail to clearly define your innovation ‘starting point,’ or lack the necessary capabilities or resources to overcome these innovation ‘nodes,’ the more efforts you make, the more troubles you will encounter. Consequently, your likelihood of failure will increase, and so will your costs.”

Therefore, at the very beginning of the translation process, scientists need to predefine the key “starting points” and “nodes” in the innovation process, all of which must be benchmarked against the market.